PB-718
/ PegBio
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
May 21, 2024
A Phase 1b/2a Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of PB-718, a GLP-1R/GCGR Dual Agonist in Subjects with Obesity
(ADA 2024)
- P1/2 | "Introduction: PB-718 is a fixed dose combination of PB-119 (GLP-1 receptor agonist) and PB-722 (glucagon receptor agonist in clinical development. PB-718 was safe, had predicted PK profile, and led to greater reductions in BW, HbA1c, blood lipids, uric acid, liver fat content and visceral fat mass. These data highlight the potential for PB-718 to provide additional benefit, and support the development of PB-718 as a promising treatment for obesity and NASH."
Clinical • P1/2 data • PK/PD data • Diabetes • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Obesity
April 19, 2024
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-718 Injection in Chinese Obese Subjects.
(clinicaltrials.gov)
- P1/2 | N=36 | Completed | Sponsor: PegBio Co., Ltd. | Recruiting ➔ Completed
Trial completion • Genetic Disorders • Obesity
November 27, 2023
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-718 Injection in Chinese Obese Subjects.
(clinicaltrials.gov)
- P1/2 | N=36 | Recruiting | Sponsor: PegBio Co., Ltd.
New P1/2 trial • Genetic Disorders • Obesity
September 28, 2022
A Phase 1, Double-blind, Randomized, Placebo-controlled, Single- and Multiple-dose Escalating Study
(clinicaltrials.gov)
- P1 | N=82 | Completed | Sponsor: PegBio Co., Ltd. | Recruiting ➔ Completed
Trial completion
September 16, 2021
A Phase 1, Double-blind, Randomized, Placebo-controlled, Single- and Multiple-dose Escalating Study
(clinicaltrials.gov)
- P1; N=80; Recruiting; Sponsor: PegBio Co., Ltd.; Initiation date: Aug 2019 ➔ Jul 2020
Clinical • Trial initiation date
August 25, 2021
A Phase 1, Double-blind, Randomized, Placebo-controlled, Single- and Multiple-dose Escalating Study
(clinicaltrials.gov)
- P1; N=80; Recruiting; Sponsor: PegBio Co., Ltd.
Clinical • New P1 trial
1 to 6
Of
6
Go to page
1